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Neuroblastoma is an embryonic neoplasm of the sympathetic nervous system that accounts for 
approximately 15 percent of all pediatric cancer fatalities. Genomic change in neuroblastoma has been 
shown to correlate with both behavior and outcome. More speciﬁ  cally, ampliﬁ  cation of the MYCN 
oncogene occurs in about 20% of neuroblastoma patients and has been shown to provide important 
prognostic information. This correlation has typically led to a multidisciplinary approach in the treatment 
of this condition, including preventive screening, dose-intensive chemotherapy, stem-cell transplantation, 
targeted therapies (radiation, monoclonal antibodies, prodifferentiation agents), and monitoring of 
minimal disease. However, although MYCN has been associated with high-risk tumors, more than 
60% of patients with aggressive disease do not exhibit this mutation, suggesting that other genetic 
mechanisms are involved in the pathophysiology of neuroblastoma. Consequently, the development 
of additional genetic markers could be useful not only in further understanding the molecular biology 
underlying these tumors, but also deﬁ  ning more effective therapy and aiding prognosis in this patient 
population.
To this end, Attiyeh and colleagues published the results of their study investigating the effects of 
loss of heterozygosity (LOH) at chromosomes 1p and 11q on relapse and survival in neuroblastoma 
(1). LOH at chromosome arms 1p and 11q are noted frequently in neuroblastoma, and previous studies 
have suggested an association with high-risk features. Furthermore, 11q23 LOH is rarely observed in 
association with MYCN ampliﬁ  cation. Given this fact, Attiyeh and colleagues hypothesized that 11q23 
LOH could be a useful prognostic marker. In this study 915 samples of neuroblastoma were screened 
for LOH at chromosome bands 1p36 and 11q23, and associations with event-free and overall survival 
were performed.
Results were as follows: patients in whom tumors showed 1p36 LOH had three-year event-free and 
overall survival rates of 47% and 64% respectively, as compared with 77% and 85%, respectively, in 
those patients who did not have 1p36 LOH. Similarly, unbalanced 11q LOH (unb11q LOH) was strongly 
associated with both decreased event-free and decreased overall survival. Analysis of the subgroup of 
cases without MYCN ampliﬁ  cation showed that both 1p36 LOH and unb11q LOH were highly associ-
ated with decreases in both event-free and overall survival. More speciﬁ  cally, patients with unb11q 
LOH had three-year event-free and overall survival rates of 50% and 66%, respectively, as compared 
with 74% (P < 0.001) and 83% (P < 0.001) in those that did. Finally, in a multivariate analysis, unb11q 
LOH was found to be independently associated with decreased event-free survival. Based on these 
ﬁ  ndings, the authors conclude that 1p36 and unb11q LOH are risk factors that should be incorporated 
into clinical trials of neuroblastoma.
This study highlights the growing importance of genetic markers for use in stratiﬁ  cation of tumor 
behavior. A number of markers including, MYCN ampliﬁ  cation, HER2/neu over-expression, chromo-
some 17 gain, Trk expression, and CD44 genetic aberrations have proven useful, and the ability to detect 
risk factors at the time of diagnosis and tailor therapy accordingly could make the treatment of cancer 
both more effective and less toxic. Of greatest concern in neuroblastoma is the rare patient who despite 
a favorable clinical proﬁ  le and no MYCN ampliﬁ  cation progresses to high-risk disease. This study, 420
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although somewhat limited by the small numbers 
within subgroups, demonstrates that 1p36 LOH 
and unb11q LOH are strongly associated with 
outcome in patients with neuroblastoma. It is the 
Figure 1. Coronal T1-weighted image demonstrating a large, left, 
paraspinal neuroblastoma in the mid/lower thoracic region.
hope of the authors’ that recognition and appreciation 
of these additional genetic markers will allow 
clinicians to more effectively tailor currently used 
prognostic schemes and treatment regimens.
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